US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

50.75

+4.178.95%

Post-market: 51.740.9900+1.95%17:43 EST

Volume:733.26K

Turnover:36.60M

Market Cap:2.19B

PE:-14.54

High:51.44

Open:47.57

Low:47.36

Close:46.58

52wk High:57.50

52wk Low:13.37

Shares:43.22M

Float Shares:21.08M

Volume Ratio:0.60

T/O Rate:3.48%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4892

EPS(LYR):-2.5506

ROE:-28.57%

ROA:-18.82%

PB:4.01

PE(LYR):-19.90

Loading ...

Overview Company News Filings

Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing

Simply Wall St.

Dianthus Therapeutics nimmt am Guggenheim Emerging Outlook: Biotech Summit teil

U.S. RESEARCH ROUNDUP-Air Products, Chevron, UnitedHealth

BRIEF-Dianthus Therapeutics May Issue Up To $600 Million In Securities

Dianthus files $600M mixed securities shelf

Dianthus Therapeutics Inc - May Issue up to $600 Mln in Securities - SEC Filing

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Dianthus Therapeutics (DNTH) and Biogen (BIIB)

Dianthus Therapeutics (DNTH) Is Up 15.5% After Positive Phase II MaGic gMG Data Revealed

Simply Wall St.

Assessing Whether Dianthus Therapeutics (DNTH) Valuation Still Holds After Recent Share Price Pullback

Simply Wall St.

Dianthus price target raised to $63 from $56 at Truist

Is Dianthus Therapeutics (DNTH) Using DNTH212’s Phase 1 Start To Redefine Its Autoimmune Strategy?

Simply Wall St.

Dianthus, Partner Say First Subject Dosed in Phase 1 Trial of Autoimmune Disease Treatment; Shares Up Pre-Bell

MT Newswires Live

Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus

Leads Biolabs and Dianthus Therapeutics Announce Initiation of Phase 1 Trial of Lbl-047 (Dnth212) in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS

Nanjing Leads Biolabs Co Ltd: Top-Line Results in Healthy Volunteers Anticipated in 2H'26

THOMSON REUTERS

Dianthus Therapeutics Licenses Global Rights to LBL-047 from Leads Biolabs

Dianthus Therapeutics CFO & CBO Ryan Savitz Reports Disposal of Common Shares

13D Filings -- Barrons.com

Dianthus Therapeutics Joins Evercore Healthcare Conference

Dianthus Therapeutics (DNTH): Assessing Valuation Following Positive Claseprubart Trial Results and Pipeline Progress

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DNTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DNTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNTH\",,,,,undefined,":{"symbol":"DNTH","market":"US","secType":"STK","nameCN":"Dianthus Therapeutics Inc.","latestPrice":50.75,"timestamp":1770411600000,"preClose":46.58,"halted":0,"volume":733264,"hourTrading":{"tag":"盘后","latestPrice":51.74,"preClose":50.75,"latestTime":"17:43 EST","volume":17306,"amount":878378.5,"timestamp":1770417821693,"change":0.99,"changeRate":0.019507,"amplitude":0.019507},"delay":0,"changeRate":0.0895234006011164,"floatShares":21075200,"shares":43223090,"eps":-3.489224,"marketStatus":"Market Closed","change":4.17,"latestTime":"02-06 16:00:00 EST","open":47.57,"high":51.44,"low":47.36,"amount":36597919.705872,"amplitude":0.087591,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.489224,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":46.58,"preHourTrading":{"tag":"盘前","latestPrice":46.57,"preClose":46.58,"latestTime":"09:22 EST","volume":135,"amount":6332.550300000001,"timestamp":1770387766192,"change":-0.01,"changeRate":-0.000215,"amplitude":0.032417},"postHourTrading":{"tag":"盘后","latestPrice":51.74,"preClose":50.75,"latestTime":"17:43 EST","volume":17306,"amount":878378.5,"timestamp":1770417821693,"change":0.99,"changeRate":0.019507,"amplitude":0.019507},"volumeRatio":0.5995996803754743,"impliedVol":0.6453,"impliedVolPercentile":0.4422},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNTH\",,,,,undefined,":{"symbol":"DNTH","floatShares":21075200,"roa":"-18.82%","roe":"-28.57%","lyrEps":-2.55056,"volumeRatio":0.5995996803754743,"shares":43223090,"dividePrice":0,"high":51.44,"amplitude":0.087591,"preClose":46.58,"low":47.36,"week52Low":13.365,"pbRate":"4.01","psRate":"712.66","week52High":57.5,"institutionHeld":0,"latestPrice":50.75,"eps":-3.489224,"divideRate":0,"volume":733264,"delay":0,"ttmEps":-3.489224,"open":47.57,"prevYearClose":41.21,"prevWeekClose":53.39,"prevMonthClose":53.39,"prevQuarterClose":41.21,"fiveDayClose":53.39,"twentyDayClose":38.12,"sixtyDayClose":36.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DNTH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-05","symbol":"DNTH","fiscalQuarterEnding":"2025/09","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"post","actualEps":-0.97},{"market":"US","date":"2025-08-07","symbol":"DNTH","fiscalQuarterEnding":"2025/06","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2025-05-12","symbol":"DNTH","fiscalQuarterEnding":"2025/03","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.82},{"market":"US","date":"2025-03-11","symbol":"DNTH","fiscalQuarterEnding":"2024/12","expectedEps":-0.85,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"DNTH","fiscalQuarterEnding":"2024/09","expectedEps":-0.59,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.74}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DNTH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DNTH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4667,"buy":0.5333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5333,"analysts":15,"updateTime":1760677200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DNTH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DNTH","date":"2026-02-05","current":-14.544781,"percent":0.087413,"low":-21.520733,"twenty":-14.870091,"median":-11.081437,"eighty":-5.986178,"high":-2.378652,"avg":-10.791641,"sd":4.423015,"marketCap":2080327321},"quantilePoints":[{"date":"2023-09-22","current":-6.821887,"twenty":-6.869759,"median":-6.842701,"eighty":-6.807317,"marketCap":194260047},{"date":"2023-09-29","current":-5.576152,"twenty":-6.838538,"median":-5.576152,"eighty":-5.435929,"marketCap":201460812},{"date":"2023-10-06","current":-4.920135,"twenty":-6.800032,"median":-5.4757,"eighty":-5.354747,"marketCap":177759540},{"date":"2023-10-13","current":-4.916034,"twenty":-6.077097,"median":-5.403948,"eighty":-4.942276,"marketCap":177611407},{"date":"2023-10-20","current":-5.11694,"twenty":-5.587632,"median":-5.309646,"eighty":-5.016077,"marketCap":184869921},{"date":"2023-10-27","current":-4.75613,"twenty":-5.576152,"median":-5.262494,"eighty":-4.957036,"marketCap":171834222},{"date":"2023-11-03","current":-4.920135,"twenty":-5.49415,"median":-5.12514,"eighty":-4.920135,"marketCap":177759540},{"date":"2023-11-10","current":-4.678228,"twenty":-5.457249,"median":-5.084139,"eighty":-4.879133,"marketCap":169019695},{"date":"2023-11-17","current":-3.935775,"twenty":-5.444949,"median":-4.957036,"eighty":-4.76023,"marketCap":169663374},{"date":"2023-11-24","current":-4.021709,"twenty":-5.412148,"median":-4.920135,"eighty":-4.674948,"marketCap":173367815},{"date":"2023-12-01","current":-3.842966,"twenty":-5.377707,"median":-4.920135,"eighty":-3.993522,"marketCap":165662579},{"date":"2023-12-08","current":-3.640162,"twenty":-5.338346,"median":-4.907834,"eighty":-3.949524,"marketCap":156920099},{"date":"2023-12-15","current":-2.684576,"twenty":-5.297345,"median":-4.846332,"eighty":-3.884902,"marketCap":115726721},{"date":"2023-12-22","current":-3.007688,"twenty":-5.267824,"median":-4.788931,"eighty":-3.85534,"marketCap":129655417},{"date":"2023-12-29","current":-3.482043,"twenty":-5.235843,"median":-4.75818,"eighty":-3.842966,"marketCap":150103929},{"date":"2024-01-05","current":-4.482315,"twenty":-5.235843,"median":-4.715129,"eighty":-3.861528,"marketCap":193223616},{"date":"2024-01-12","current":-4.05952,"twenty":-5.169421,"median":-4.670027,"eighty":-3.873902,"marketCap":174997769},{"date":"2024-01-19","current":-3.952961,"twenty":-5.12186,"median":-4.521845,"eighty":-3.879402,"marketCap":170404263},{"date":"2024-01-26","current":-6.135656,"twenty":-5.267824,"median":-4.661827,"eighty":-3.893152,"marketCap":264495873},{"date":"2024-02-02","current":-14.091886,"twenty":-5.428549,"median":-4.735629,"eighty":-3.901401,"marketCap":607473021},{"date":"2024-02-09","current":-15.77856,"twenty":-5.593373,"median":-4.788931,"eighty":-3.913775,"marketCap":680182147},{"date":"2024-02-16","current":-16.247836,"twenty":-6.141843,"median":-4.875033,"eighty":-3.933712,"marketCap":700411702},{"date":"2024-02-23","current":-16.322648,"twenty":-6.585949,"median":-4.911934,"eighty":-3.935775,"marketCap":703636704},{"date":"2024-03-01","current":-16.832731,"twenty":-6.855189,"median":-4.920135,"eighty":-3.939212,"marketCap":725625351},{"date":"2024-03-08","current":-17.220393,"twenty":-14.108208,"median":-4.920135,"eighty":-3.952961,"marketCap":742336722},{"date":"2024-03-15","current":-18.274564,"twenty":-15.869694,"median":-5.055438,"eighty":-3.952961,"marketCap":787779926},{"date":"2024-03-22","current":-19.002283,"twenty":-16.27504,"median":-5.103895,"eighty":-3.958461,"marketCap":819150396},{"date":"2024-03-28","current":-20.617859,"twenty":-16.390659,"median":-5.12104,"eighty":-3.98046,"marketCap":898010856},{"date":"2024-04-05","current":-16.662734,"twenty":-16.662734,"median":-5.235843,"eighty":-3.987335,"marketCap":725745374},{"date":"2024-04-12","current":-16.777278,"twenty":-16.777278,"median":-5.350646,"eighty":-3.990772,"marketCap":730734324},{"date":"2024-04-19","current":-15.922581,"twenty":-16.832731,"median":-5.444949,"eighty":-3.99421,"marketCap":693508032},{"date":"2024-04-26","current":-14.143673,"twenty":-16.777278,"median":-5.535151,"eighty":-4.021709,"marketCap":616027659},{"date":"2024-05-03","current":-16.178636,"twenty":-16.662734,"median":-5.637242,"eighty":-4.021709,"marketCap":704660510},{"date":"2024-05-10","current":-14.570862,"twenty":-16.662734,"median":-6.140812,"eighty":-4.049207,"marketCap":731661246},{"date":"2024-05-17","current":-15.342363,"twenty":-16.621896,"median":-6.530951,"eighty":-4.05952,"marketCap":770401432},{"date":"2024-05-24","current":-12.724299,"twenty":-16.45867,"median":-6.737265,"eighty":-4.100768,"marketCap":638937940},{"date":"2024-05-31","current":-12.098897,"twenty":-16.404261,"median":-6.842701,"eighty":-4.106268,"marketCap":607534008},{"date":"2024-06-07","current":-12.233329,"twenty":-16.390659,"median":-12.098897,"eighty":-4.121392,"marketCap":614284386},{"date":"2024-06-14","current":-15.75779,"twenty":-16.354335,"median":-12.233329,"eighty":-4.176389,"marketCap":791261684},{"date":"2024-06-21","current":-15.114854,"twenty":-16.327131,"median":-12.630781,"eighty":-4.296009,"marketCap":758977268},{"date":"2024-06-28","current":-14.565435,"twenty":-16.324142,"median":-12.706764,"eighty":-4.381256,"marketCap":731388767},{"date":"2024-07-05","current":-15.459702,"twenty":-16.325636,"median":-12.794437,"eighty":-4.452753,"marketCap":776293455},{"date":"2024-07-12","current":-16.932611,"twenty":-16.417863,"median":-13.066224,"eighty":-4.47819,"marketCap":850254116},{"date":"2024-07-15","current":-16.920921,"twenty":-16.466954,"median":-13.180199,"eighty":-4.480252,"marketCap":849667127},{"date":"2024-08-02","current":-16.371502,"twenty":-16.45867,"median":-13.180199,"eighty":-4.482315,"marketCap":822078626},{"date":"2024-08-09","current":-13.845994,"twenty":-16.50009,"median":-13.738229,"eighty":-4.561374,"marketCap":784804801},{"date":"2024-08-16","current":-15.438194,"twenty":-16.45867,"median":-13.792112,"eighty":-4.661827,"marketCap":875052279},{"date":"2024-08-23","current":-14.304023,"twenty":-16.390659,"median":-14.112289,"eighty":-4.678228,"marketCap":810766318},{"date":"2024-08-30","current":-14.899592,"twenty":-16.390659,"median":-14.219338,"eighty":-4.715129,"marketCap":844523786},{"date":"2024-09-06","current":-14.490462,"twenty":-16.375333,"median":-14.311791,"eighty":-4.74793,"marketCap":821333873},{"date":"2024-09-13","current":-14.402421,"twenty":-16.338396,"median":-14.319559,"eighty":-4.75941,"marketCap":816343639},{"date":"2024-09-20","current":-14.552608,"twenty":-16.324142,"median":-14.311791,"eighty":-4.783191,"marketCap":824856392},{"date":"2024-09-27","current":-13.993291,"twenty":-16.306326,"median":-14.304023,"eighty":-4.815172,"marketCap":793153726},{"date":"2024-10-04","current":-14.221161,"twenty":-16.285922,"median":-14.291076,"eighty":-4.861093,"marketCap":806069627},{"date":"2024-10-11","current":-14.672555,"twenty":-16.269355,"median":-14.319559,"eighty":-4.877493,"marketCap":831655088},{"date":"2024-10-18","current":-14.522306,"twenty":-16.254626,"median":-14.311791,"eighty":-4.902094,"marketCap":823138846},{"date":"2024-10-25","current":-14.475677,"twenty":-16.248614,"median":-14.360865,"eighty":-4.914394,"marketCap":820495874},{"date":"2024-10-31","current":-14.486039,"twenty":-16.239675,"median":-14.366036,"eighty":-4.918495,"marketCap":821083201},{"date":"2024-11-08","current":-13.087312,"twenty":-16.213004,"median":-14.381745,"eighty":-4.920135,"marketCap":878053924},{"date":"2024-11-15","current":-11.244659,"twenty":-16.189942,"median":-14.360865,"eighty":-4.920135,"marketCap":754426637},{"date":"2024-11-22","current":-8.941908,"twenty":-16.180782,"median":-14.311791,"eighty":-4.920135,"marketCap":599930480},{"date":"2024-11-29","current":-10.582949,"twenty":-16.17095,"median":-14.273283,"eighty":-4.920135,"marketCap":710031190},{"date":"2024-12-06","current":-10.437372,"twenty":-16.142849,"median":-14.241876,"eighty":-4.934895,"marketCap":700264191},{"date":"2024-12-13","current":-10.36679,"twenty":-16.097823,"median":-14.188265,"eighty":-4.996397,"marketCap":695528677},{"date":"2024-12-20","current":-10.163866,"twenty":-16.05809,"median":-14.112289,"eighty":-5.061998,"marketCap":681914073},{"date":"2024-12-27","current":-10.14622,"twenty":-16.019613,"median":-14.091886,"eighty":-5.076759,"marketCap":680730195},{"date":"2025-01-03","current":-10.234448,"twenty":-15.922581,"median":-13.957579,"eighty":-5.096439,"marketCap":686649588},{"date":"2025-01-10","current":-11.284361,"twenty":-15.89482,"median":-13.822388,"eighty":-5.108369,"marketCap":757090364},{"date":"2025-01-17","current":-8.474299,"twenty":-15.887478,"median":-13.728741,"eighty":-5.115822,"marketCap":568557697},{"date":"2025-01-24","current":-9.828599,"twenty":-15.834329,"median":-13.708453,"eighty":-5.12186,"marketCap":659420380},{"date":"2025-01-31","current":-9.603618,"twenty":-15.788231,"median":-13.553088,"eighty":-5.191562,"marketCap":644325928},{"date":"2025-02-07","current":-10.128574,"twenty":-15.779567,"median":-13.462457,"eighty":-5.235843,"marketCap":679546316},{"date":"2025-02-14","current":-10.644708,"twenty":-15.766098,"median":-13.180199,"eighty":-5.267824,"marketCap":714174765},{"date":"2025-02-21","current":-10.455018,"twenty":-15.745542,"median":-13.087312,"eighty":-5.305545,"marketCap":701448070},{"date":"2025-02-28","current":-9.285997,"twenty":-15.702913,"median":-12.81575,"eighty":-5.346546,"marketCap":623016113},{"date":"2025-03-07","current":-10.375613,"twenty":-15.663831,"median":-12.724299,"eighty":-5.384267,"marketCap":696120616},{"date":"2025-03-14","current":-8.045567,"twenty":-15.60664,"median":-12.588406,"eighty":-5.420348,"marketCap":683623809},{"date":"2025-03-21","current":-7.727979,"twenty":-15.500032,"median":-12.233329,"eighty":-5.449869,"marketCap":656638658},{"date":"2025-03-28","current":-7.512473,"twenty":-15.459702,"median":-12.013661,"eighty":-5.472009,"marketCap":638327306},{"date":"2025-04-04","current":-6.416037,"twenty":-15.451099,"median":-11.624039,"eighty":-5.526951,"marketCap":545164287},{"date":"2025-04-11","current":-5.898066,"twenty":-15.431979,"median":-11.290978,"eighty":-5.587632,"marketCap":501152792},{"date":"2025-04-17","current":-7.175981,"twenty":-15.413286,"median":-11.262304,"eighty":-5.60754,"marketCap":609735897},{"date":"2025-04-25","current":-8.026663,"twenty":-15.369114,"median":-11.0285,"eighty":-5.622077,"marketCap":682017550},{"date":"2025-05-02","current":-8.204554,"twenty":-15.321347,"median":-10.898364,"eighty":-5.689407,"marketCap":697132746},{"date":"2025-05-09","current":-7.796217,"twenty":-15.230244,"median":-10.759405,"eighty":-5.898822,"marketCap":662436738},{"date":"2025-05-16","current":-5.986178,"twenty":-15.201008,"median":-10.704262,"eighty":-5.916298,"marketCap":602999662},{"date":"2025-05-23","current":-5.861665,"twenty":-15.193619,"median":-10.675588,"eighty":-5.916298,"marketCap":590457269},{"date":"2025-05-30","current":-5.698841,"twenty":-15.181369,"median":-10.600594,"eighty":-5.861665,"marketCap":574055678},{"date":"2025-06-06","current":-5.92871,"twenty":-15.126544,"median":-10.582949,"eighty":-5.698841,"marketCap":597210865},{"date":"2025-06-13","current":-6.15858,"twenty":-15.114854,"median":-10.503543,"eighty":-5.724382,"marketCap":620366052},{"date":"2025-06-20","current":-5.567944,"twenty":-15.086799,"median":-10.455018,"eighty":-5.687986,"marketCap":560870086},{"date":"2025-06-27","current":-5.788235,"twenty":-15.056571,"median":-10.424138,"eighty":-5.643102,"marketCap":583060473},{"date":"2025-07-03","current":-6.018104,"twenty":-15.025316,"median":-10.371201,"eighty":-5.641637,"marketCap":606215660},{"date":"2025-07-11","current":-6.580007,"twenty":-15.002134,"median":-10.30503,"eighty":-5.677131,"marketCap":662817229},{"date":"2025-07-18","current":-6.496998,"twenty":-14.98745,"median":-10.28959,"eighty":-5.714166,"marketCap":654455633},{"date":"2025-07-25","current":-6.956737,"twenty":-14.950568,"median":-10.234448,"eighty":-5.730129,"marketCap":700766007},{"date":"2025-08-01","current":-6.599162,"twenty":-14.912021,"median":-10.163866,"eighty":-5.73396,"marketCap":664746827},{"date":"2025-08-08","current":-6.113883,"twenty":-14.897039,"median":-10.14622,"eighty":-5.764609,"marketCap":615863655},{"date":"2025-08-15","current":-5.680098,"twenty":-14.891675,"median":-10.102106,"eighty":-5.714166,"marketCap":651813986},{"date":"2025-08-22","current":-6.633794,"twenty":-14.884329,"median":-10.031524,"eighty":-5.730129,"marketCap":761254359},{"date":"2025-08-29","current":-6.959172,"twenty":-14.857999,"median":-9.84404,"eighty":-5.73396,"marketCap":798592839},{"date":"2025-09-05","current":-6.917097,"twenty":-14.83641,"median":-9.826394,"eighty":-5.754393,"marketCap":793764587},{"date":"2025-09-12","current":-10.61968,"twenty":-14.806372,"median":-9.828599,"eighty":-5.786319,"marketCap":1218650741},{"date":"2025-09-19","current":-13.100588,"twenty":-14.770844,"median":-9.916203,"eighty":-5.789512,"marketCap":1503344826},{"date":"2025-09-26","current":-12.079369,"twenty":-14.762402,"median":-10.031524,"eighty":-5.797813,"marketCap":1386155868},{"date":"2025-10-03","current":-12.446738,"twenty":-14.758601,"median":-10.102106,"eighty":-5.811222,"marketCap":1428312952},{"date":"2025-10-10","current":-11.711999,"twenty":-14.750427,"median":-10.14622,"eighty":-5.817199,"marketCap":1343998784},{"date":"2025-10-17","current":-12.133294,"twenty":-14.726754,"median":-10.163866,"eighty":-5.821144,"marketCap":1392344064},{"date":"2025-10-24","current":-11.213186,"twenty":-14.705712,"median":-10.234448,"eighty":-5.826546,"marketCap":1286757972},{"date":"2025-10-31","current":-11.371593,"twenty":-14.704884,"median":-10.28959,"eighty":-5.834208,"marketCap":1304935797},{"date":"2025-11-07","current":-11.48051,"twenty":-14.703303,"median":-10.30503,"eighty":-5.84678,"marketCap":1450505040},{"date":"2025-11-14","current":-12.047161,"twenty":-14.690699,"median":-10.355761,"eighty":-5.85115,"marketCap":1522098532},{"date":"2025-11-21","current":-13.706615,"twenty":-14.666007,"median":-10.410904,"eighty":-5.857834,"marketCap":1731762245},{"date":"2025-11-28","current":-14.924905,"twenty":-14.703472,"median":-10.441784,"eighty":-5.865182,"marketCap":1885687139},{"date":"2025-12-05","current":-15.172635,"twenty":-14.705712,"median":-10.501337,"eighty":-5.879885,"marketCap":1916986630},{"date":"2025-12-12","current":-14.127417,"twenty":-14.759182,"median":-10.582949,"eighty":-5.885547,"marketCap":1784928504},{"date":"2025-12-19","current":-14.16814,"twenty":-14.753642,"median":-10.600594,"eighty":-5.898822,"marketCap":1790073626},{"date":"2025-12-26","current":-14.643239,"twenty":-14.756857,"median":-10.62529,"eighty":-5.901847,"marketCap":1850100047},{"date":"2026-01-02","current":-13.984887,"twenty":-14.743997,"median":-10.660148,"eighty":-5.923337,"marketCap":1766920578},{"date":"2026-01-09","current":-12.936275,"twenty":-14.712726,"median":-10.702056,"eighty":-5.944035,"marketCap":1634433691},{"date":"2026-01-16","current":-14.931692,"twenty":-14.757438,"median":-10.748376,"eighty":-5.968854,"marketCap":1886544660},{"date":"2026-01-23","current":-17.904456,"twenty":-14.780844,"median":-10.845427,"eighty":-5.981347,"marketCap":2262138551},{"date":"2026-01-30","current":-18.10807,"twenty":-14.824694,"median":-10.944683,"eighty":-5.986178,"marketCap":2287864160},{"date":"2026-02-05","current":-16.46545,"twenty":-14.870091,"median":-11.081437,"eighty":-5.986178,"marketCap":2080327321}],"updateTime":1770433852320},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DNTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609547526","title":"Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2609547526","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609547526?lang=en_us&edition=fundamental","pubTime":"2026-02-07 15:06","pubTimestamp":1770447990,"startTime":"0","endTime":"0","summary":"What Dianthus Therapeutics’ New Shelf Registration Means For Investors\nDianthus Therapeutics (DNTH) recently filed a US$600 million universal shelf registration covering common and preferred stock, debt securities, warrants, and units, giving the company flexibility to access capital over time.\nFor you as an investor, a shelf like this does not mean an immediate offering. However, it does open the door to future fundraisings or transactions that could affect dilution, liquidity, and how the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/assessing-dianthus-therapeutics-dnth-valuation-after-new-us6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/assessing-dianthus-therapeutics-dnth-valuation-after-new-us6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2609374194","title":"Dianthus Therapeutics nimmt am Guggenheim Emerging Outlook: Biotech Summit teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374194","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609374194?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292850,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. wird am 12. Februar 2026 am Guggenheim Emerging Outlook: Biotech Summit in New York City teilnehmen. CEO Marino Garcia nimmt an einem Analystengesprch teil und führt Einzelgesprche mit Investoren.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLfy7HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","DNTH","IE00B64PRP62.GBP","BK4139","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2608618856","title":"U.S. RESEARCH ROUNDUP-Air Products, Chevron, UnitedHealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2608618856","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608618856?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:05","pubTimestamp":1770019550,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Air Products, Chevron, UnitedHealthFeb 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Air Produ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nL8N3YY0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABT","BA","BX","GGLL","CAT","EXP","AMD","GOU","GOOW","BTSG","AWK","CHTR","DAMD","CVX","ARCB","CF","ELV","DECK","HSY","CL","ABCB","EMN","ASTH","GOOGL","DNTH","APD","BBY","AMAT","CCB","BXP","CHD","BBNX","AXP","GGLS","ARE","ADSK","AMDU","CFR","BC","BKR","EGBN","CSW","DOW","BKU","AMP","GOOX","ACAD","DOV","GOOY","GOOP"],"gpt_icon":0},{"id":"2607729334","title":"BRIEF-Dianthus Therapeutics May Issue Up To $600 Million In Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2607729334","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607729334?lang=en_us&edition=fundamental","pubTime":"2026-01-29 06:45","pubTimestamp":1769640313,"startTime":"0","endTime":"0","summary":"BRIEF-Dianthus Therapeutics May Issue Up To $600 Million In Securities Jan 28  - Dianthus Therapeutics Inc DNTH.O:DIANTHUS THERAPEUTICS INC - MAY ISSUE UP TO $600 MILLION IN SECURITIES - SEC FILINGSource text: [ID:n0001193125-26-027273]Further company coverage: DNTH.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT1EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2607234177","title":"Dianthus files $600M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2607234177","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607234177?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:31","pubTimestamp":1769635904,"startTime":"0","endTime":"0","summary":"16:26 EST Dianthus (DNTH) files $600M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dianthus-files-600m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dianthus-files-600m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2607728718","title":"Dianthus Therapeutics Inc - May Issue up to $600 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2607728718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607728718?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:25","pubTimestamp":1769635548,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT1EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2606716092","title":"Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Dianthus Therapeutics (DNTH) and Biogen (BIIB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606716092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606716092?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:41","pubTimestamp":1769604087,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zimmer Biomet Holdings (ZBH – Research Report), Dianthus Therapeu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zimmer-biomet-holdings-zbh-dianthus-therapeutics-dnth-and-biogen-biib-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zimmer-biomet-holdings-zbh-dianthus-therapeutics-dnth-and-biogen-biib-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4533","BK4566","LU0889566641.SGD","LU0128526141.USD","BK4585","LU1201861249.SGD","BK4137","IE00B7SZLL34.SGD","LU0109394709.USD","LU0310799852.SGD","LU0211327993.USD","LU0889565916.HKD","LU1267930813.SGD","IE00B19Z9Z06.USD","LU0029874061.USD","LABU","IE00B894F039.SGD","LU0708994859.HKD","LU1267930490.SGD","LU0980610538.SGD","DNTH","BK4532","IE00B19Z9P08.USD","ZBH","LU0128525929.USD","IE00B19Z3581.USD","LU0320765992.SGD","LU0029864427.USD","LU0310800379.SGD","LU0234570918.USD","BK4588","LU0006061336.USD","LU0130102774.USD","LU0211328371.USD","HCSG","LU0477156953.USD","IE0002270589.USD","BIIB","LU0648001328.SGD","LU0792757196.USD","BK4581","LU1267930573.SGD","XBI","LU0130517989.USD","XLV","BK4504","BK4139","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2604973119","title":"Dianthus Therapeutics (DNTH) Is Up 15.5% After Positive Phase II MaGic gMG Data Revealed","url":"https://stock-news.laohu8.com/highlight/detail?id=2604973119","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604973119?lang=en_us&edition=fundamental","pubTime":"2026-01-18 17:21","pubTimestamp":1768728104,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics recently highlighted positive Phase II MaGic trial data for its complement inhibitor Claseprubart (DNTH103) in generalized myasthenia gravis and presented its broader pipeline story at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, led by President and CEO Marino Garcia.\nThe combination of clinically meaningful efficacy, favorable tolerability, and growing interest in mechanism-based therapies positions Claseprubart as a potentially important...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/dianthus-therapeutics-dnth-is-up-155-after-positive-phase-ii","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/dianthus-therapeutics-dnth-is-up-155-after-positive-phase-ii","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2602053432","title":"Assessing Whether Dianthus Therapeutics (DNTH) Valuation Still Holds After Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2602053432","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602053432?lang=en_us&edition=fundamental","pubTime":"2026-01-11 07:29","pubTimestamp":1768087748,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics (DNTH) has been drawing fresh attention after its recent share price moves, prompting investors to weigh how its clinical stage autoimmune drug pipeline lines up with current revenue, losses, and recent return patterns.\nSee our latest analysis for Dianthus Therapeutics.\nThe recent pullback, with a 30 day share price return of a 12.37% decline and a year to date share price return of a 3.75% decline at a latest share price of $38.19, contrasts with a 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/assessing-whether-dianthus-therapeutics-dnth-valuation-still","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/assessing-whether-dianthus-therapeutics-dnth-valuation-still","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2601645653","title":"Dianthus price target raised to $63 from $56 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2601645653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601645653?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:55","pubTimestamp":1767876953,"startTime":"0","endTime":"0","summary":"Truist raised the firm’s price target on Dianthus (DNTH) to $63 from $56 and keeps a Buy rating on the shares. The firm updated its model, but tell...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dianthus-price-target-raised-to-63-from-56-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dianthus-price-target-raised-to-63-from-56-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2601486228","title":"Is Dianthus Therapeutics (DNTH) Using DNTH212’s Phase 1 Start To Redefine Its Autoimmune Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601486228","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601486228?lang=en_us&edition=fundamental","pubTime":"2026-01-07 02:26","pubTimestamp":1767724009,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs and Dianthus Therapeutics recently reported that the first subject has been dosed in a two-part, placebo-controlled Phase 1 trial of LBL-047 (DNTH212), a bifunctional fusion protein targeting BDCA2 and TACI for potential treatment of systemic lupus erythematosus and other autoimmune diseases.\nThis follows their exclusive global partnership, worth up to US$1.00 billion, under which Dianthus holds rights to develop and commercialize DNTH212 outside Greater China,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/is-dianthus-therapeutics-dnth-using-dnth212s-phase-1-start-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/is-dianthus-therapeutics-dnth-using-dnth212s-phase-1-start-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2593492554","title":"Dianthus, Partner Say First Subject Dosed in Phase 1 Trial of Autoimmune Disease Treatment; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2593492554","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593492554?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:48","pubTimestamp":1766490511,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics (DNTH) and partner Nanjing Leads Biolabs said Tuesday the first subject was dosed in a phase 1 clinical trial of the LBL-047 bifunctional fusion protein developed by Nanjing.The ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2593494536","title":"Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2593494536","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593494536?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:14","pubTimestamp":1766488480,"startTime":"0","endTime":"0","summary":"Dec 23 (Reuters) - Nanjing Leads Biolabs <9887.HK>::*LEADS BIOLABS AND DIANTHUS THERAPEUTICS ANNOUNCE INITIATION OF PHASE 1 TRIAL OF LBL-047 (DNTH212) IN HEALTHY VOLUNTEERS AND PATIENTS WITH SYSTEMIC ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nRSD1cYslf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","HK0000500386.USD","BK4139","HK0000252160.HKD","HK0000252152.HKD","BK1161","09887"],"gpt_icon":0},{"id":"2593491782","title":"Leads Biolabs and Dianthus Therapeutics Announce Initiation of Phase 1 Trial of Lbl-047 (Dnth212) in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (Sle)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593491782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593491782?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:00","pubTimestamp":1766487627,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT03P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2593491711","title":"Nanjing Leads Biolabs Co Ltd:  Top-Line Results in Healthy Volunteers Anticipated in 2H'26","url":"https://stock-news.laohu8.com/highlight/detail?id=2593491711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593491711?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:00","pubTimestamp":1766487627,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT03P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","09887","DNTH","BK1161","HK0000252160.HKD","HK0000252152.HKD","BK4139"],"gpt_icon":0},{"id":"2593491769","title":"Dianthus Therapeutics Licenses Global Rights to LBL-047 from Leads Biolabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2593491769","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593491769?lang=en_us&edition=fundamental","pubTime":"2025-12-23 19:00","pubTimestamp":1766487627,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. has entered into an exclusive global partnership with Leads Biolabs, with the total potential deal value reaching up to $1 billion. Under the agreement, Dianthus has licensed exclusive global rights from Leads Biolabs to research, develop, manufacture, and commercialize LBL-047 . Both companies will jointly advance the global development of DNTH212 to maximize its clinical and commercial potential. Dianthus expects to provide an update on prioritized indications for DNTH212 in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 23, 2025, and is solely responsible for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL6Ffy6p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4585","DNTH","LU2095319765.USD","BK4139","IE00B3QW5Z07.USD","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2589617846","title":"Dianthus Therapeutics CFO & CBO Ryan Savitz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589617846","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589617846?lang=en_us&edition=fundamental","pubTime":"2025-12-06 09:00","pubTimestamp":1764982834,"startTime":"0","endTime":"0","summary":"Ryan Savitz, CFO & CBO of Dianthus Therapeutics Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL8NDQjH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus Therapeutics CFO & CBO Ryan Savitz Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2589432528","title":"13D Filings -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2589432528","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589432528?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:35","pubTimestamp":1764977700,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 27 through Dec. 3, 2025. Source: VerityData. Insight Enterprises ValueAct Capital lowered its stake in the enterprise information-technology company to 1,446,739 shares. ValueAct Capital did so through the sale of 220,000 Insight Enterprises shares from Oct. 29 through Dec. 1 at per share prices ranging from $85 to $105.09. Following the latest sales, ValueAct Capital continues to own 4.7% of Insight Enterprises' outstanding stock, placing ValueAct below the 5% threshold that would require it to report further sales. Shares of Insight Enterprises have lost approximately 40.6% of their value since the beginning of this","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4140","ASH","USDT.USD.CC","LU2463526074.USD","BK4139","BK4109","BK4600","BK4535","BK4023","DNTH","BK4595","USDT.USD.HKCC","NSIT","BTDR","BK4539","CNTA"],"gpt_icon":0},{"id":"2585618734","title":"Dianthus Therapeutics Joins Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585618734","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585618734?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985624,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. CEO Marino Garcia is scheduled to take part in a fireside chat on Tuesday, December 2, 2025, at 2:35 p.m. ET and will also hold one-on-one meetings with investors. A webcast of the presentation will be available on the company's website in the Investors section under \"News and Events.\". Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLc16kvh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","BK4588","DNTH","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","BK4127","EVR"],"gpt_icon":0},{"id":"2582330761","title":"Dianthus Therapeutics (DNTH): Assessing Valuation Following Positive Claseprubart Trial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2582330761","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582330761?lang=en_us&edition=fundamental","pubTime":"2025-11-11 14:18","pubTimestamp":1762841905,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics (DNTH) caught investor attention after announcing statistically significant positive results from its Phase 2 trial for claseprubart in generalized myasthenia gravis. The company now plans to launch Phase 3 studies.\nSee our latest analysis for Dianthus Therapeutics.\nThe market has clearly taken notice of Dianthus Therapeutics’ recent milestones. The share price is up nearly 84% over the past 90 days, and there has been a robust year-to-date increase of 58% following...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/dianthus-therapeutics-dnth-assessing-valuation-following-pos","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/dianthus-therapeutics-dnth-assessing-valuation-following-pos","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU2065732104.USD","PRGS","DNTH","BK4097"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":59,"code":"91000000","status":"200"}]}}